Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC

Benoit Tessoulin 1, 2 P Ceballos 3 P. Chevallier 1 Didier Blaise 4 Olivier Tournilhac 5 J. Gauthier 6 N. Maillard 7 Reza Tabrizi 8 S. Choquet 9 S. Carras 10 Norbert Ifrah 11 G. Guillerm 12 Mohamad Mohty 13 Herve Tilly 14 Gérard Socié 15 J. Cornillon 16 Olivier Hermine 17 E. Daguindau 18 E. Bachy 19 S. Girault 20 T. Marchand 21 L. Oberic 22 O. Reman 23 C. Leux 24 Steven Le Gouill 25, 2
Abstract : Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell lymphoma (MCL). Despite this intensive treatment, transplant patients remain highly susceptible to relapse over time. The French SFGM-TC performed a national survey on reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) for fit relapsed/refractory patients who failed after auto-SCT (n=106). Median times of relapse after auto-SCT, and from auto-SCT to RIC-allo-SCT were 28 months and 3.6 years, respectively. Sixty per cent of patients received at least three lines of treatment before RIC-allo-SCT. Conditioning regimens for RIC-allo-SCT were heterogeneous. Twenty patients experienced grade III/IV aGvHD, extensive cGvHD was reported in 28 cases. Median follow-up after RIC-allo-SCT was 45 months. Median PFS after RIC-allo-SCT was 30.1 months and median overall survival was 62 months. Treatment-related mortality (TRM) at 1 year and 3 years were estimated at 28% and 32%, respectively. A total of 52 patients died; major causes of death were related to toxicity (n=34) and MCL (n=11). Patients in good response before RIC-allo-SCT experienced a better PFS and OS. Our work highlights the need for new RIC-allo-SCT MCL-tailored approaches to reduce TRM, and early and late relapse.
Type de document :
Article dans une revue
Bone Marrow Transplantation, Nature Publishing Group, 2016, 51 (9), pp.1184-1190. 〈10.1038/bmt.2016.102〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01419584
Contributeur : Elizabeth Bernardo <>
Soumis le : lundi 19 décembre 2016 - 16:41:38
Dernière modification le : vendredi 27 juillet 2018 - 15:20:02

Identifiants

Citation

Benoit Tessoulin, P Ceballos, P. Chevallier, Didier Blaise, Olivier Tournilhac, et al.. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplantation, Nature Publishing Group, 2016, 51 (9), pp.1184-1190. 〈10.1038/bmt.2016.102〉. 〈inserm-01419584〉

Partager

Métriques

Consultations de la notice

320